ストックスクリーナーアプリを入手
23.00
0.61%
0.14
アフターアワーズ：
23.00
Zymeworks Inc. (ZYME) 最新ニュース
Zymeworks Inc (ZYME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SummitTX Capital L.P. Purchases 97,159 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zymeworks Inc (ZYME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Zymeworks Inc. Revenue Breakdown – LSX:A3DSSN - TradingView
Zymeworks Inc. (ZYME) Stock Analysis: A 70% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
ZYME|Zymeworks Inc|Price:22.860|Chg%:-0.260 - TradingKey
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm
Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade
Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative
Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why - Yahoo Finance
ETFs Investing in Zymeworks Inc. Stocks - TradingView
Hillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYME - MarketBeat
Pictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYME - MarketBeat
Theravance stock down 3% after Zymeworks announces buyout - MSN
Zymeworks ZW49 from ZYMEantibody drug conjugate targets solid tumors - Ad-hoc-news.de
Zymeworks Inc outlines its biotech strategy as investors track clinical progress - ad-hoc-news.de
Zymeworks: A Deep Dive (NASDAQ:ZYME) - Seeking Alpha
Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Nigeria
Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan
Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com
Zymeworks (ZYME) Breaks Out: +2.29% Rally Tests Key Resistance Near $27.63Buffered ETF - dars.gov.et
Enterprise value to EBIT forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - Ad-hoc-news.de
Zymeworks Inc. (ZYME): Exploring the Potential of an Undervalued Biotech in OncologyEarnings Stability Report - dars.gov.et
ZYME Q1 2026 Earnings: Wide EPS Miss Amid No Revenue as Operating Losses DeepenReturn On Assets - dars.gov.et
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Enterprise value to revenue forward of Zymeworks Inc. – BOATS:ZYME - TradingView
The Zymeworks ZW25 bispecific antibodya flexible HER2 therapy option for oncology partners - ad-hoc-news.de
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Insider Monkey
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Zymeworks Inc. (ZYME) M&A CallSlideshow (NASDAQ:ZYME) 2026-06-30 - Seeking Alpha
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
Zymeworks to buy troubled U.S.-Irish pharma company Theravance for US$929M - The Logic
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% Upside - TradingView
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
Stifel reiterates Zymeworks stock Buy rating at $47 target By Investing.com - Investing.com South Africa
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com UK
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Zymeworks (ZYME) M&A announcement Summary - Quartr
Theravance, after clinical setbacks, agrees to $929M buyout - BioPharma Dive
Zymeworks bolsters royalty stream with Theravance buy - BioWorld News
B. Riley reiterates buy on Zymeworks stock after Theravance acquisition - Investing.com
Zymeworks to Acquire Theravance Biopharma, Inc. - wahanariau.com
B. Riley reiterates buy on Zymeworks stock after Theravance acquisition By Investing.com - Investing.com India
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive
Zymeworks to Acquire Theravance for $929 Million, But Discounted Price Triggers Shareholder Investigation - finance.biggo.com
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):